Sevion Therapeutics Presents Cow Antibody Platform At Protein Discovery Summit

SAN DIEGO--(BUSINESS WIRE)--Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCBB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, will give an invited oral presentation entitled “Engineering Cow Antibodies with Ultralong CDRs” at the GTC Protein Discovery Summit conference in Boston, MA on October 22, 2015. “Antibodies with unique features, such as long target binding regions, are becoming more important in drug discovery. Our unique humanized cow scaffold has potential to address many challenging targets like ion channels,” noted Dr. Smider. “The discovery of the structural and genetic features of cow antibodies were featured in the journal Cell just two years ago, and we are excited to share our progress in engineering these exciting next-generation antibodies for therapeutics.”

“The discovery of the structural and genetic features of cow antibodies were featured in the journal Cell just two years ago, and we are excited to share our progress in engineering these exciting next-generation antibodies for therapeutics.”

About Sevion Therapeutics

Sevion Therapeutics is a biopharmaceutical company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit SevionTherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to continue as a going concern; the ability of the Company to consummate additional financings; the development of the Company’s antibody technology; the approval of the Company’s patent applications; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.